Sinphar Pharmaceutical Co.,Ltd.

NT$29.90As of Sun 8 Nov 2026, 12:00 UTC
TWSE:1734Healthcare
Country Taiwan
PE (Fwd) •••
TSR 10Y CAGR 5.09%
Div yield 3.15%
ROE 9.42%
Biotechnology
Beta (5Y) 0.14
PE TTM 17.22
TSR TTM 1.71%
Mkt cap NT$6.028B
ROIC 8.07%
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$31
4.97%
290.53%
Hold 11|12|9|1|6
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.46
0.50
0.53
0.59
34.64%
37.43%
38.47%
41.06%
RevenueNT$M
744.7
767.6
748.4
788.5
11.43%
14.42%
7.69%
11.96%
Peers (US$182.1M)
Cap (US$)
PE
192.3M
—
184.3M
5.939x
Capital
TTM
5Y
10Y
Leveragex
1.110
(0.038)
—
EBIT/Intx
0.479
0.196
0.222
Own earn%
(86.12)
(135.46)
(110.90)
Sh yield%
47.92
23.88
23.69
Owners
Insiders/Inst%
5.01
30.85
Short interest%
4.14
SBC / revenue%
1.74
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
15
Op margin range%
1–7
$1 testx
—
Incr. ROIC%
4